Roche Gains U.S. Breakthrough Therapy Designation for Actemra Drug.

1 post in this topic

Just read about this this morning. Is anyone on this? 


Roche Gains US Breakthrough Therapy Designation for Actemra Drug.


The U.S. Food and Drug Administration research showed early treatment with Actemra could prevent irreversible damage to joints in patients with systemic sclerosis and held stave off long-term disability. Dow Jones Business News, 06/10/2015. (Also see Scleroderma Clinical Trials)


This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now